Y&L Advance Health care, Inc. D/B/A Elite Clinical Research
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hernandez, Beatriz
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT05539352: Improving Caregivers' Ability to Manage Life Stress

Withdrawn
N/A
10
US
Problem Solving Therapy (PST) plus EUC, PST plus EUC
VA Office of Research and Development
Suicidal Ideation
02/25
02/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hernandez, Beatriz
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT05539352: Improving Caregivers' Ability to Manage Life Stress

Withdrawn
N/A
10
US
Problem Solving Therapy (PST) plus EUC, PST plus EUC
VA Office of Research and Development
Suicidal Ideation
02/25
02/25

Download Options